ORAL PRESENTATIONS 2023

O1: Disease Course of Crohn’s Disease Patients Undergoing Primary Bowel Resection; a Population-based Study

O2: A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease

O3: Pre-operative systemic corticosteroids and long-term outcomes after primary ileocaecal resection in Crohn’s Disease

O4: A serum protein signature for IBD: Diagnostic and prediction modelling using two independent inception cohorts

POSTERS 2023

P1: The Effect of Appendectomy on the Clinical Course of Ulcerative Colitis: one-year results ACCURE-trial

P2: Prospective study on patients switching from intravenous to subcutaneous vedolizumab maintenance treatment – 18-month follow-up

P3: Maternal diet quality during pregnancy and association with the offspring’s risk of inflammatory bowel disease

P4: High tumour-stroma ratio in colitis-associated colorectal cancer indicates worse prognosis

P5: Exclusive enteral nutrition downstages complicated Crohn’s disease prior to surgical resection: A feasibility study

P6: Tofacitinib real-world experience in ulcerative colitis in Finland; results from different University hospital catchment areas

P7: Biomarkers to improve diagnosis and prognosis in patients with suspected IBD: The NORDTREAT Cohort Study

P8: Retracted

P9: Atopic manifestations in early life and risk of inflammatory bowel disease: preliminary findings from a Scandinavian birth cohort study

P10: Histological remission in inflammatory bowel disease and female fertility: A nationwide study

P11: Quality of life and outcomes in patients operated with continent ileostomy at Sahlgrenska University Hospital

P12: Income and work participation in patients with IBD onset in childhood or young adulthood

P13: Long-term impact of COVID-19 infection on IBD outcomes: a systematic review and meta-analysis

P14: Relationship and sexuality in IBD: results from a patient questionnaire

P15: Stress and IBD – are there any differences during flare and remission?

P16: Comparative analysis of point-of-care testing and in-house ELISA for infliximab concentrations in inflammatory bowel disease

P17: Loss of tolerance toward microbial antigens differs with age at CD diagnosis: A twin study

P18: Graft survival in liver transplanted patients with inflammatory bowel disease associated primary sclerosing cholangitis

P19: The Nordic IBD Treatment Strategy Trial (NORDTREAT): Protocol for a randomised controlled biomarker-stratified trial

P20: Increase of angiotensin converting enzyme 2 (ACE2) in the inflamed mucosa of Crohn’s disease